An advanced cancer diagnosis can feel overwhelming, leaving you and your loved ones with many questions.
For those seeking answers, genomic testing, also known as biomarker testing, can help. Ask your doctor about Foundation Medicine’s testing options, including FoundationOne®CDx, FoundationOne®Liquid CDx, and FoundationOne®Heme. These tests can help you and your doctor create a personalized treatment plan, which can mean more options and more power over your diagnosis.
Foundation Medicine uses comprehensive genomic profiling, a type of biomarker testing, that looks at more genes to find information in your tumor’s DNA. These insights may help you and your doctor create a personalized treatment plan.
A personalized cancer treatment plan matters. Watch this video to discover our approach to biomarker testing.
Foundation Medicine offers different testing options for all cancer types. Your doctor will determine which test is right for you based on your cancer type.
Food and Drug Administration (FDA)–approved test for all solid tumors performed on a tissue biopsy. It uses biomarker testing to analyze over 300 genes from a single tissue sample.
Laboratory-developed test (LDT)* for blood cancers like leukemia and lymphoma that analyzes over 400 genes and biomarkers. The test can be performed on blood, bone marrow, or a tissue biopsy.
FDA-approved test for all solid tumors that analyzes over 300 genes from just a simple blood draw, called a liquid biopsy.
Ask your doctor about the Foundation Medicine testing options. This guide will help prepare you for the discussion.
Hear Summer’s story as she reflects on her cancer journey and how she worked with her doctor to create a personalized treatment plan.
Discover how the FoundationOne CDx test helped Ed, a patient with Stage 4 colon cancer, and his loved one, Sandy, create a personalized cancer treatment plan together with a doctor.
Watch Christine Bray, an ovarian cancer patient, share how the FoundationOne CDx biomarker test helped guide her path to remission.
See how Peggy, Don, & Karen have advocated for themselves and other patients, and how Foundation Medicine's biomarker tests enabled personalized approach to their cancer treatment.
FoundationOne®Heme is a laboratory developed test that was developed and its performance characteristics determined by Foundation Medicine. FoundationOne Heme has not been cleared or approved by the U.S. Food and Drug Administration. For more information on FoundationOne Heme, please see its Technical Specifications at www.foundationmedicine.com/heme.
FoundationOne®CDx and FoundationOne®Liquid CDx are for prescription use only and are FDA-approved qualitative next-generation sequencing based in vitro diagnostic tests for advanced cancer patients with solid tumors. FoundationOne CDx utilizes FFPE tissue and analyzes 324 genes as well as genomic signatures. FoundationOne Liquid CDx analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes, rearrangements in 8 genes and copy number alterations in 3 genes. The tests are companion diagnostics to identify patients who may benefit from treatment with specific therapies in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the tests does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy which may pose a risk. When considering eligibility for ROZLYTREK® based on the detection of NTRK1/2/3 and ROS1 fusions, or for TEPMETKO® based on the detection of MET SNVs and indels that lead to MET exon 14 skipping, testing using plasma specimens is only appropriate for patients for whom tumor tissue is not available for testing. Patients who are tested with FoundationOne Liquid CDx and are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete labels, including companion diagnostic indications and important risk information, please visit www.F1CDxLabel.com and www.F1LCDxLabel.com.
